NCT02639338 - Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis | Biotech Hunter

Enrollment

220

Participants

Timeline

Start Date

December 23, 2015

Primary Completion Date

October 12, 2016

Study Completion Date

January 2, 2017

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

SOF/VEL/VOX

400/100/100 mg FDC tablet administered orally once daily with food

DRUG

SOF/VEL

400/100 mg FDC tablet administered orally once daily without regard to food

Trial Locations (70)

Unknown

Long Beach

Los Angeles

Palo Alto

Rialto

San Diego

San Francisco

Aurora

Miami

Wellington

Atlanta

Indianapolis

Bastrop

Baltimore

Catonsville

Boston

Ann Arbor

Detroit

Hillsborough

New York

The Bronx

Asheville

Fayetteville

Pittsburgh

Providence

Nashville

San Antonio

Murray

Norfolk

Richmond

Seattle

Camperdown

Darlinghurst

Herston

Clayton

Fitzroy

Melbourne

Calgary

Edmonton

Vancouver

Brampton

Toronto

Bobigny

Clermont-Ferrand

Clichy

Créteil

Limoges

Lyon

Marseille

Montpellier

Nice

Orléans

Paris

Pessac

Rennes

Strasbourg

Vandœuvre-lès-Nancy

Berlin

Bonn

Cologne

Frankfurt am Main

Hamburg

Hanover

Grafton

Christchurch

San Juan

London

Manchester

Nottingham

Oxford

Portsmouth